Vratislav Strnad, MD, PhD, on Multicatheter Brachytherapy After Breast-Conserving Surgery 
    		2015 ASTRO Annual Meeting
    	
    	
    	
    
        Vratislav Strnad, MD, PhD, of the University Hospital in Erlangen, discusses results from a European study comparing accelerated partial-breast irradiation using brachytherapy, to the standard treatment of whole-breast irradiation for women with low-risk breast cancer (Abstract LBA7).
    
    
    
    
       
       
    		Brian D. Kavanagh, MD
		
		
        
		
		
		
		Brian D. Kavanagh, MD, of the University of Colorado School of Medicine, summarizes three papers: outcomes for locally advanced non–small cell lung cancer, 3D CRT vs image-guided intensity-modulated radiotherapy for reducing bowel toxicity, and dexamethasone for controlling pain flares in patients with bone metastases (Abstracts 2, 8, LBA6663).
			
			
     	
    
       
       
    		Robert Kuske, MD
		
		
        
		
		
		
		Robert Kuske, MD, of Arizona Breast Cancer Specialists, discusses the evaluation of more than 1,300 patients with accelerated partial-breast irradiation via multicatheter interstitial brachytherapy, focusing on toxicity and cosmetic outcomes (Abstract 133).
			
			
     	
    
       
       
    		Roy Decker, MD, PhD
		
		
        
		
		
		
		Roy Decker, MD, PhD, of Yale University School of Medicine, discusses a National Cancer Database analysis that showed elderly patients with limited-stage small cell lung cancer can benefit from adding concurrent radiation to chemotherapy (Abstract 1010).
			
			
     	
    
       
       
    		Anita Mahajan, MD
		
		
        
		
		
		
		Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).
			
			
     	
    
       
       
    		Reshma Jagsi, MD, DPhil
		
		
        
		
		
		
		Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).